Efficacy Of Ertugliflozin Compared With Metformin Or Placebo In Reducing Hba1c Levels Among Adults With Type 2 Diabetes: A Systematic Review And Meta-Analysis
Abstract
Type 2 diabetes mellitus (T2DM) remains a global health challenge characterized by chronic hyperglycemia due to insulin resistance and impaired insulin secretion. Glycemic control, measured by glycated hemoglobin (HbA1c), is a crucial indicator of therapeutic effectiveness. This systematic review and meta-analysis aim to compare the efficacy of Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with Metformin and Placebo in reducing HbA1c levels among adults with T2DM. Relevant randomized controlled trials (RCTs) published between 2015 and 2025 were identified through PubMed, Scopus, and Cochrane databases. Data extraction and quality assessment followed PRISMA guidelines. The pooled analysis demonstrated that Ertugliflozin significantly reduced HbA1c levels compared to placebo, with mean differences ranging from −0.6% to −1.0% (p < 0.001). When compared to Metformin, Ertugliflozin showed comparable glycemic efficacy, with additional benefits in weight reduction and blood pressure control. Heterogeneity among studies was moderate (I² < 50%), and no severe adverse effects were reported. These findings suggest that Ertugliflozin is an effective and safe alternative or adjunct therapy for adults with T2DM, offering multifaceted metabolic benefits beyond glucose control.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.